ReNerve achieves first sales of amniotic tissue range
| Stock | RNV.ASX (RNV.ASX) |
|---|---|
| Release Time | 14 Oct 2025, 9:06 a.m. |
| Price Sensitive | Yes |
ReNerve achieves first sales of amniotic tissue range
- First commercial sale of ReNerve's EmpliQ™ amniotic tissue products
- EmpliQ™ range showcased at ASSH annual meeting, featuring three minimally processed products designed to support faster post-surgical recovery
- EmpliQ™ products complement ReNerve's NervAlign® range and can be used in wound management associated with peripheral nerve repair and broader applications
ReNerve Limited, a pioneering Australian medical device company developing innovative products for peripheral nerve injury repair, has announced that it has achieved the first sale of its EmpliQ amniotic tissue products. The company featured the three products in the EmpliQ range at the recent American Society for Surgery of the Hand (ASSH) annual meeting in Vancouver, Canada. The amniotic tissue is minimally processed and used in the treatment of wounds as the endogenous growth factors and cytokines aid a faster recovery post-surgery. The EmpliQ amniotic range is complementary to the Company's NervAlign® product range and can be used in the treatment of wounds associated with peripheral nerve repairs. The three products in the EmpliQ range are each designed to assist with the recovery of all wounds, from surgical wounds through to diabetic ulcers. ReNerve CEO Dr Julian Chick stated that this is an important step forward for the company as it transitions from a pure R&D focus to commercial activities. The products have regulatory clearance in the major US market and are well suited to ReNerve's existing sales and distribution channels, and the company expects the EmpliQ range to continue expanding revenue growth.
ReNerve achieved 53% revenue growth in FY25, reaching $271k in sales. The global market for peripheral nerve repair is estimated to be around USD$1.6 billion and growing at 17+%. The global dermal and amniotic tissue market is estimated to be worth around USD$2.7 billion in 2024 and growing at around 12% CAGR.
ReNerve is leveraging its eCOO technology, already proven through its NervAlign® Nerve Cuff, to develop and bring to market a range of nerve conduit products. The company is also progressing the development of its proprietary nerve guide matrix, aimed at the treatment of more severe nerve injuries.